![](https://investorshub.advfn.com/uicon/158678.png?cb=1661594561)
Tuesday, January 28, 2020 8:22:40 AM
(adjusted for split)
Last February NNVC made an offering of 6,944,446 (347,223) shares at $.36 ($7.20) per share, tossing in an equal amount of warrants exercisable at $.61 ($12.20) per share.
One of the terms of the offering was the requirement for an adjustment of the exercise price in the event that the Company attempted to sell shares below the exercise price of the warrants, which is exactly what the Company did with the recent offering priced at $3.
The only way to avoid violating that term was to price the recent offering at $12.20 and they obviously would have found it impossible to sell shares at that price.
So last year's investors forced the Company to not only re-issue their $12.20 warrants to them at an exercise price of $3 but also to issue them 677,224 shares of Common Stock (worth multiple millions at yesterday's price or what's left of it today...you do the math) or the recent offering could have been held up.
But the "settlement" comes with a funny kicker, which is undoubtedly one reason for the excessive payoff:
"The New Warrants are, subject to the availability of authorized shares of Common Stock of which there are none today, immediately exercisable and expire on August 27, 2024."
That's my reading of it and I welcome any corrections to it if anyone sees it some other way.
But can it core A apple?
Yes Ralph, of course it can core A apple.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM